<p>Arcellx（納斯達克代碼：ACLX - 獲取免費報告）在週一發佈給投資者的研究報告中被 Truist Financial 的研究分析師升級為 “強力買入” 評級，Zacks.com 報道。</p>
<p>其他幾位股票研究分析師最近也對該股票發表了看法。TD Cowen 在 3 月 2 日的報告中將 Arcellx 的評級從 “強力買入” 下調至 “持有”。Guggenheim 在 2 月 25 日的報告中將 Arcellx 的評級從 “買入” 下調至 “中性”，並將其目標價格從 120.00 美元下調至 115.00 美元。Leerink Partners 在 2 月 24 日的研究報告中重申了 “市場表現” 評級，並對 Arcellx 的股票設定了 115.00 美元的目標價格。Weiss Ratings 在 4 月 20 日的研究報告中重申了對 Arcellx 的 “賣出（d-）” 評級。最後，William Blair 在 2 月 23 日的研究報告中將 Arcellx 的評級從 “強力買入” 下調至 “持有”。一位股票研究分析師給予該股票 “強力買入” 評級，一位給予 “買入” 評級，十六位給予 “持有” 評級，一位給予 “賣出” 評級。根據 MarketBeat.com 的數據，該股票的平均評級為 “持有”，共識目標價格為 111.87 美元。</p>
<p><strong>閲讀我們關於 Arcellx 的最新報告</strong></p>
<h2>Arcellx 價格表現</h2>
<p>ACLX 股票在週一開盤價為 115.10 美元。Arcellx 的 1 年最低價為 47.86 美元，1 年最高價為 115.13 美元。該股票的 50 日移動平均線為 110.81 美元，200 日移動平均線為 87.46 美元。公司的市值為 67.3 億美元，市盈率為-28.28，貝塔值為 0.25。</p>
<p>Arcellx（納斯達克代碼：ACLX - 獲取免費報告）於 2 月 26 日星期四發佈了其季度財報。公司報告每股收益為（1.01 美元），符合分析師的共識預期（1.01 美元）。Arcellx 的淨利潤率為-1,027.26%，股本回報率為-55.42%。該業務的季度收入為 165 萬美元，而分析師預期為 1,340 萬美元。分析師預計 Arcellx 在當前年度的每股收益為-2.91。</p>
<h2>內部人士下注</h2>
<p>在其他消息中，內部人士 Rami Elghandour 於 2 月 27 日星期五出售了 89,916 股該股票。該股票以 113.92 美元的平均價格出售，總價值為 10,243,230.72 美元。交易後，內部人士直接持有 276,051 股公司股票，價值約為 31,447,729.92 美元。這代表其持股比例減少了 24.57%。該出售在向證券交易委員會提交的文件中披露，該文件可通過 SEC 網站訪問。內部人士持有公司 8.35% 的股票。</p>
<h2>對 Arcellx 的對沖基金看法</h2>
<p>幾家對沖基金和其他機構投資者最近也買賣了 ACLX 的股票。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.在第一季度將其在 Arcellx 的持倉增加了 5.1%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.現在擁有 28,753 股公司股票，價值 1,893,000 美元，此前在上個季度又購買了 1,390 股。Empowered Funds LLC 在第一季度購買了 Arcellx 的新股份，價值 1,768,000 美元。Intech Investment Management LLC 在第一季度將其在 Arcellx 的持倉增加了 27.7%。Intech Investment Management LLC 現在擁有 21,967 股公司股票，價值 1,441,000 美元，此前在上個季度又購買了 4,760 股。Prudential Financial Inc.在第二季度將其在 Arcellx 的持倉增加了 49.2%。Prudential Financial Inc.現在擁有 4,900 股公司股票，價值 323,000 美元，此前在上個季度又購買了 1,615 股。最後，挪威銀行在第二季度購買了 Arcellx 的新股份，價值 739,000 美元。機構投資者和對沖基金持有公司 96.03% 的股票。</p>
<h2>關於 Arcellx</h2>
<p>（獲取免費報告）</p>
<p>Arcellx, Inc（納斯達克代碼：ACLX）是一家臨牀階段的生物製藥公司，專注於發現、開發和商業化下一代細胞療法，用於腫瘤和自身免疫疾病。公司的專有 ARC-SparX™平台旨在實現對細胞表面受體激活的精確控制，並提高採用細胞療法的安全性、有效性和持久性。利用這一技術，Arcellx 對免疫細胞進行工程改造，使其具有可交換的模塊化抗原結合域，以針對多種與疾病相關的標記。</p>
<p>公司的產品管線包括多個在血液惡性腫瘤和實體腫瘤領域的全資項目，處於不同的臨牀前和臨牀開發階段。</p>
<h2>另見</h2>
<ul>
<li>我們更看好的五隻股票，勝過 Arcellx</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUNMWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUNMWA"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Arcellx 嗎？</h2>
<p>在你考慮 Arcellx 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦，現在購買，以便在更廣泛的市場注意到之前……而 Arcellx 並不在名單上。</p>
<p>雖然 Arcellx 目前在分析師中獲得 “持有” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

ACLX

<p>Truist Financial 將 Arcellx (NASDAQ:ACLX) 的評級上調至 “強力買入”。其他分析師的看法不一，TD Cowen 將其評級下調至 “持有”，Guggenheim 則下調了其目標股價。該股票開盤價為 115.10 美元，1 年區間為 47.86 至 115.13 美元。Arcellx 報告季度每股虧損為（1.01）美元，未能達到收入預期。內部人士出售了股份，機構投資者持有該股票的 96.03%。Arcellx 專注於開發用於腫瘤學和自身免疫疾病的細胞療法</p>

<p>Arcellx (NASDAQ:ACLX - Get Free Report) was upgraded by research analysts at Truist Financial to a &#34;strong-buy&#34; rating in a research note issued to investors on Monday,Zacks.com reports.</p>
<div class="lb-trans"><p>Arcellx（納斯達克代碼：ACLX - 獲取免費報告）在週一發佈給投資者的研究報告中被 Truist Financial 的研究分析師升級為 “強力買入” 評級，Zacks.com 報道。</p>
</div><p>Several other equities research analysts also recently weighed in on the stock. TD Cowen lowered shares of Arcellx from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a report on Monday, March 2nd. Guggenheim lowered Arcellx from a &#34;buy&#34; rating to a &#34;neutral&#34; rating and decreased their price objective for the company from $120.00 to $115.00 in a report on Wednesday, February 25th. Leerink Partners reissued a &#34;market perform&#34; rating and issued a $115.00 price objective on shares of Arcellx in a research report on Tuesday, February 24th. Weiss Ratings restated a &#34;sell (d-)&#34; rating on shares of Arcellx in a research note on Monday, April 20th. Finally, William Blair cut Arcellx from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research note on Monday, February 23rd. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, sixteen have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of &#34;Hold&#34; and a consensus price target of $111.87.</p>
<div class="lb-trans"><p>其他幾位股票研究分析師最近也對該股票發表了看法。TD Cowen 在 3 月 2 日的報告中將 Arcellx 的評級從 “強力買入” 下調至 “持有”。Guggenheim 在 2 月 25 日的報告中將 Arcellx 的評級從 “買入” 下調至 “中性”，並將其目標價格從 120.00 美元下調至 115.00 美元。Leerink Partners 在 2 月 24 日的研究報告中重申了 “市場表現” 評級，並對 Arcellx 的股票設定了 115.00 美元的目標價格。Weiss Ratings 在 4 月 20 日的研究報告中重申了對 Arcellx 的 “賣出（d-）” 評級。最後，William Blair 在 2 月 23 日的研究報告中將 Arcellx 的評級從 “強力買入” 下調至 “持有”。一位股票研究分析師給予該股票 “強力買入” 評級，一位給予 “買入” 評級，十六位給予 “持有” 評級，一位給予 “賣出” 評級。根據 MarketBeat.com 的數據，該股票的平均評級為 “持有”，共識目標價格為 111.87 美元。</p>
</div><p><strong>Read Our Latest Report on Arcellx</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 Arcellx 的最新報告</strong></p>
</div><h2>Arcellx Price Performance</h2>
<div class="lb-trans"><h2>Arcellx 價格表現</h2>
</div><p>Shares of ACLX stock opened at $115.10 on Monday. Arcellx has a 1-year low of $47.86 and a 1-year high of $115.13. The stock's 50-day moving average is $110.81 and its 200 day moving average is $87.46. The company has a market cap of $6.73 billion, a P/E ratio of -28.28 and a beta of 0.25.</p>
<div class="lb-trans"><p>ACLX 股票在週一開盤價為 115.10 美元。Arcellx 的 1 年最低價為 47.86 美元，1 年最高價為 115.13 美元。該股票的 50 日移動平均線為 110.81 美元，200 日移動平均線為 87.46 美元。公司的市值為 67.3 億美元，市盈率為-28.28，貝塔值為 0.25。</p>
</div><p>Arcellx (NASDAQ:ACLX - Get Free Report) last released its quarterly earnings results on Thursday, February 26th. The company reported ($1.01) earnings per share for the quarter, meeting analysts' consensus estimates of ($1.01). Arcellx had a negative net margin of 1,027.26% and a negative return on equity of 55.42%. The business had revenue of $1.65 million for the quarter, compared to analysts' expectations of $13.40 million. On average, analysts anticipate that Arcellx will post -2.91 EPS for the current year.</p>
<div class="lb-trans"><p>Arcellx（納斯達克代碼：ACLX - 獲取免費報告）於 2 月 26 日星期四發佈了其季度財報。公司報告每股收益為（1.01 美元），符合分析師的共識預期（1.01 美元）。Arcellx 的淨利潤率為-1,027.26%，股本回報率為-55.42%。該業務的季度收入為 165 萬美元，而分析師預期為 1,340 萬美元。分析師預計 Arcellx 在當前年度的每股收益為-2.91。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>內部人士下注</h2>
</div><p>In other news, insider Rami Elghandour sold 89,916 shares of the stock in a transaction dated Friday, February 27th. The stock was sold at an average price of $113.92, for a total value of $10,243,230.72. Following the transaction, the insider directly owned 276,051 shares of the company's stock, valued at approximately $31,447,729.92. This represents a 24.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which is accessible through the SEC website. Insiders own 8.35% of the company's stock.</p>
<div class="lb-trans"><p>在其他消息中，內部人士 Rami Elghandour 於 2 月 27 日星期五出售了 89,916 股該股票。該股票以 113.92 美元的平均價格出售，總價值為 10,243,230.72 美元。交易後，內部人士直接持有 276,051 股公司股票，價值約為 31,447,729.92 美元。這代表其持股比例減少了 24.57%。該出售在向證券交易委員會提交的文件中披露，該文件可通過 SEC 網站訪問。內部人士持有公司 8.35% 的股票。</p>
</div><h2>Hedge Funds Weigh In On Arcellx</h2>
<div class="lb-trans"><h2>對 Arcellx 的對沖基金看法</h2>
</div><p>Several hedge funds and other institutional investors have recently bought and sold shares of ACLX. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Arcellx by 5.1% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 28,753 shares of the company's stock worth $1,893,000 after buying an additional 1,390 shares during the last quarter. Empowered Funds LLC purchased a new stake in shares of Arcellx in the 1st quarter valued at $1,768,000. Intech Investment Management LLC boosted its holdings in shares of Arcellx by 27.7% in the 1st quarter. Intech Investment Management LLC now owns 21,967 shares of the company's stock valued at $1,441,000 after acquiring an additional 4,760 shares during the last quarter. Prudential Financial Inc. raised its holdings in shares of Arcellx by 49.2% during the second quarter. Prudential Financial Inc. now owns 4,900 shares of the company's stock worth $323,000 after purchasing an additional 1,615 shares during the last quarter. Finally, Norges Bank purchased a new position in shares of Arcellx during the second quarter worth $739,000. Institutional investors and hedge funds own 96.03% of the company's stock.</p>
<div class="lb-trans"><p>幾家對沖基金和其他機構投資者最近也買賣了 ACLX 的股票。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.在第一季度將其在 Arcellx 的持倉增加了 5.1%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.現在擁有 28,753 股公司股票，價值 1,893,000 美元，此前在上個季度又購買了 1,390 股。Empowered Funds LLC 在第一季度購買了 Arcellx 的新股份，價值 1,768,000 美元。Intech Investment Management LLC 在第一季度將其在 Arcellx 的持倉增加了 27.7%。Intech Investment Management LLC 現在擁有 21,967 股公司股票，價值 1,441,000 美元，此前在上個季度又購買了 4,760 股。Prudential Financial Inc.在第二季度將其在 Arcellx 的持倉增加了 49.2%。Prudential Financial Inc.現在擁有 4,900 股公司股票，價值 323,000 美元，此前在上個季度又購買了 1,615 股。最後，挪威銀行在第二季度購買了 Arcellx 的新股份，價值 739,000 美元。機構投資者和對沖基金持有公司 96.03% 的股票。</p>
</div><h2>About Arcellx</h2>
<div class="lb-trans"><h2>關於 Arcellx</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Arcellx, Inc NASDAQ: ACLX is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation cell therapies for oncology and autoimmune diseases. The company's proprietary ARC-SparX™ platform is designed to enable precise control over cell-surface receptor activation and to improve the safety, efficacy and durability of adoptive cell therapies. Leveraging this technology, Arcellx engineers immune cells with modular antigen-binding domains that can be exchanged to target a variety of disease-associated markers.</p>
<div class="lb-trans"><p>Arcellx, Inc（納斯達克代碼：ACLX）是一家臨牀階段的生物製藥公司，專注於發現、開發和商業化下一代細胞療法，用於腫瘤和自身免疫疾病。公司的專有 ARC-SparX™平台旨在實現對細胞表面受體激活的精確控制，並提高採用細胞療法的安全性、有效性和持久性。利用這一技術，Arcellx 對免疫細胞進行工程改造，使其具有可交換的模塊化抗原結合域，以針對多種與疾病相關的標記。</p>
</div><p>The company's pipeline comprises multiple wholly owned programs in hematologic malignancies and solid tumors at various stages of preclinical and clinical development.</p>
<div class="lb-trans"><p>公司的產品管線包括多個在血液惡性腫瘤和實體腫瘤領域的全資項目，處於不同的臨牀前和臨牀開發階段。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than Arcellx</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，勝過 Arcellx</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUNMWA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=ACLX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Arcellx Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Arcellx 嗎？</h2>
</div><p>Before you consider Arcellx, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Arcellx 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arcellx wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦，現在購買，以便在更廣泛的市場注意到之前……而 Arcellx 並不在名單上。</p>
</div><p>While Arcellx currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Arcellx 目前在分析師中獲得 “持有” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Arcellx (NASDAQ:ACLX) Upgraded to Strong-Buy at Truist Financial

Market Beat

Arcellx

Arcellx（納斯達克代碼：ACLX）在 Truist Financial 被上調至強力買入評級